Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Jun;32(6):648-55.
doi: 10.1097/INF.0b013e318284129a.

Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants

Patricia A Sirois  1 , Yanling Huo, Paige L Williams, Kathleen Malee, Patricia A Garvie, Betsy Kammerer, Kenneth Rich, Russell B Van Dyke, Molly L Nozyce; Pediatric HIVAIDS Cohort Study
Collaborators, Affiliations
Multicenter Study

Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants

Patricia A Sirois et al. Pediatr Infect Dis J. 2013 Jun.

Abstract

Background: This study evaluated effects of perinatal exposure to antiretroviral (ARV) medications on neurodevelopment of HIV-exposed, uninfected infants.

Methods: HIV-exposed, uninfected infants (age 9-15 months) enrolled in Surveillance Monitoring for Antiretroviral Therapy Toxicities, a multisite prospective surveillance study, completed the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III), assessing cognition, language, motor skills, social-emotional development and adaptive behavior. Linear regression models were used to evaluate associations between Bayley-III outcomes in infants with and without perinatal and neonatal ARV exposure, by regimen (combination ARV [cARV] versus non-cARV), type of regimen (defined by drug class) and individual ARVs (for infants with cARV exposure), adjusting for maternal and infant health and demographic covariates.

Results: As of May 2010, 374 infants had valid Bayley-III evaluations. Median age at testing was 12.7 months; 49% male, 79% black and 16% Hispanic. Seventy-nine percent were exposed to regimens containing protease inhibitors (9% of protease inhibitor-containing regimens also included non-nucleoside reverse transcriptase inhibitors), 5% to regimens containing non-nucleoside reverse transcriptase inhibitors (without protease inhibitor) and 14% to regimens containing only nucleoside reverse transcriptase inhibitors. Overall, 83% were exposed to cARV. No Bayley-III outcome was significantly associated with overall exposure to cARV, ARV regimen or neonatal prophylaxis. For individual ARVs, following sensitivity analyses, the adjusted group mean on the Language domain was within age expectations but significantly lower for infants with perinatal exposure to atazanavir (P = 0.01).

Conclusions: These results support the safety of perinatal ARV use. Continued monitoring for adverse neurodevelopmental outcomes in older children is warranted, and the safety of atazanavir merits further study.

PubMed Disclaimer

References

    1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MF, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J. Med. 1994;331:1173–1180. - PubMed
    1. Heidari S, Mofenson L, Cotton MF, Marlink R, Cahn P, Katabira E. Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr. 2011;57:290–296. - PubMed
    1. Whitmore SK, Zhang X, Taylor A, Blair JM. Estimated number of infants born to HIV-infected women in the United States and five dependent areas, 2006. J Acquir Immune Defic Syndr. 2011;57:218–222. - PubMed
    1. Thorne C, Newell M-L. Safety of agents used to prevent mother-to-child transmission of HIV: Is there any cause for concern? Drug Saf. 2007;30:203–213. - PubMed
    1. Funk MJ, Belinson SE, Pimenta JM, Morsheimer M, Gibbons DC. Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy. Drug Saf. 2007;30:845–859. - PubMed

Publication types

Substances